Zhang, Bingnan
Stewart, C. Allison
Wang, Qi
Cardnell, Robert J.
Rocha, Pedro http://orcid.org/0000-0003-3221-7354
Fujimoto, Junya
Solis Soto, Luisa M.
Wang, Runsheng
Novegil, Veronica
Ansell, Peter
He, Lei
Fernandez, Luisa
Jendrisak, Adam
Gilbertson, Cole
Schonhoft, Joseph D.
Byun, Jiyun
Jones, Joshua
Anderson, Amanda K. L.
Aparicio, Ana
Tran, Hai
Negrao, Marcelo V.
Zhang, Jianjun http://orcid.org/0000-0001-7872-3477
Wang, Wei-lien
Wistuba, Ignacio I.
Wang, Jing
Wenstrup, Rick
Byers, Lauren A. http://orcid.org/0000-0002-0780-2677
Gay, Carl M. http://orcid.org/0000-0002-4907-0718
Article History
Received: 19 November 2021
Revised: 10 March 2022
Accepted: 29 March 2022
First Online: 19 April 2022
Competing interests
: IW received honorarium from Genentech/Roche, Bayer, Bristol-Myers Squibb, AstraZeneca, Pfizer, HTG Molecular, Asuragen, Merck, GlaxoSmithKline, Guardant Health, Flame, Novartis, Sanofi, Daiichi Sankyo, Amgen, Oncocyte, and MSD; and received research support from Genentech, HTG Molecular, DepArray, Merck, Bristol-Myers Squibb, Medimmune, Adaptive, Adaptimmune, EMD Serono, Pfizer, Takeda, Amgen, Karus, Johnson & Johnson, Bayer, Iovance, 4D, Novartis, and Akoya. JZ served on advisory board for AstraZeneca, Novartis, Johnson and Johnson, Geneplus and received speaker’s fees from BMS, OrigMed, Innovent, grants from Merck, Novartis, Johnson and Johnson from outside the submitted work JS received stock options from Epic Sciences at the time of this work. MN reports research funding to institution: Mirati, Novartis, Checkmate, Ziopharm, AstraZeneca, Pfizer, Genentech; consulted for Mirati, Merk and served on advisory board for MSD; meal expenses from Ziopharm. LB received research funding from AstraZeneca, GenMab, Sierra Oncology, ToleroPharmaceuticals; served as an advisor/consultant for AstraZeneca, GenMab, Sierra Oncology, PharmaMar, AbbVie, Bristol-Myers Squibb, Alethia, Merck, Pfizer, Jazz Pharmaceuticals, Genentech, Debiopharm Group. CG received research funding from AstraZeneca; served as an adviser for Bristol-Myers Squibb, Jazz Pharmaceuticals, AstraZeneca, Kisoji; and served on the Speaker’s Bureau for AstraZeneca, Beigene.
: Participants underwent informed written consent to Institutional Review Board (IRB)-approved protocol LAB10-0442 (“Evaluation of blood-based test for the detection of circulating tumour cells and circulating proteins and microRNAs and molecular analysis for polymorphisms and mutations”). The study was performed in accordance with the Declaration of Helsinki.
: Not applicable.